Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Progression-free survival, according to treatment group

Published byGiovanna Madureira Chaves Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Progression-free survival, according to treatment group"— Presentation transcript:

1 Figure 4 Progression-free survival, according to treatment group
Figure 4 | Progression-free survival, according to treatment group. Results from the Radiation Therapy Oncology Group (RTOG) 9802 trial7. a | Progression-free survival of all patients by treatment. b | Progression-free survival of patients with IDH1-Arg132His mutations by treatment group. Insufficient material was available for infrequent IDH mutations or 1p/19q codeletion. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. From The New England Journal of Medicine, Buckner, J. C. et al., Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, 374, 1344–1355. Copyright © (2016) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Buckner, J. et al. (2017) Management of diffuse low-grade gliomas in adults — use of molecular diagnostics Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 4 Progression-free survival, according to treatment group"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.
Treatment of early-stage Hodgkin lymphoma

Treatment of early-stage Hodgkin lymphoma
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 1 Histopathology of low-grade glioma

Figure 1 Histopathology of low-grade glioma
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 3 Molecular subgroups of glioblastoma,

Figure 3 Molecular subgroups of glioblastoma,
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 5 Number of AHSCT procedures for

Figure 5 Number of AHSCT procedures for
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo
Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Similar presentations

Ads by Google